You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Controversies in the management of ovarian cancer

Ozols, R. F.

International Journal of Gynecological Cancer:
Current Concepts in the Management of Ovarian Cancer: Proceedings of a satellite symposium of the 1st European Symposium of Epithelial Ovarian Cancer June 14, 1996
Author Information

Fox Chase Cancer Center, Philadelphia, PA, USA

Address for correspondence: Dr R. F. Ozols, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. Taxol® is a trademark of Bristol-Myers Squibb Company.

Abstract

A new standard chemotherapy for ovarian cancer has been accepted in the USA: paclitaxel (Taxol®) plus a platinum compound (cisplatin or carboplatin). There remain, however, many areas of controversy in treating this disease, including the role of cytoreductive surgery, the optimum combination regimen, the approach to managing patients who achieve a clinical remission, the importance of dose intensity in chemotherapy, the efficacy of intraperitoneal therapy, the benefit of whole-abdomen irradiation, and the status of immunotherapy and hormones.

© 1997 Blackwell Science Ltd.